ASAP Act

S 3267, the ASAP Act, would require Medicare to cover early detection screening tests for Alzheimer's disease and related dementias starting January 1, 2028. The bill defines these tests as FDA-cleared or approved blood, genomic, or imaging-based screenings for pre-symptomatic or early-stage detection. It directly affects Medicare beneficiaries aged 65+ who may be at risk for Alzheimer's, ensuring coverage for these specific tests once approved. The key provision adds these screenings to Medicare's payment system under Section 1833(h)(1)(A) of the Social Security Act.